Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade lymphoma Study Group
Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade lymphoma Study Group
复制标题
DOI：
10.1182/blood-2007-10-117010
复制
发表时间：
2008-02-15
期刊：
影响因子：
20.3
通讯作者：
Klapper, Wolfram
中科院分区：
文献类型：
--
作者：
Determann, Olaf;Hoster, Eva;Klapper, Wolfram
套细胞淋巴瘤（MCL）的临床结果是高度异质性的。在许多使用非均质治疗患者队列的研究中，通过Ki-67指数评估的肿瘤细胞增殖已显示出MCL的预后信息。Ki-67指数在接受抗CD 20治疗的患者中的预后价值迄今尚未研究。我们分析了在随机试验中接受治疗的249例晚期MCL患者的初步诊断时的KI-67指数。KI-67与总生存率有很高的预后相关性（Ki-67高10%的相对风险为1.27，P <0.001），也与临床预后因素无关。不同Ki-67指数小于10%、10%至小于30%和30%或更高的3组在CHOP治疗患者（P = 0.001）以及CHOP联合抗CD 20治疗患者（R-CHOP，P = 0.013）中显示出显著不同的总生存期。因此，Ki-67指数仍然是抗CD 20治疗时代的重要预后标志物。欧洲MCL研究在www. ClinicalTrials.gov作为#NCT00016887。
Clinical outcome of mantle cell lymphoma (MCL) is highly heterogeneous. Tumor cell proliferation as assessed by the Ki-67 index has been shown to yield prognostic information on MCL in many studies using heterogeneously treated patient cohorts. The prognostic value of the Ki-67 index in patients treated with anti-CD20 therapy has not been studied so far. We analyzed the KI-67 index at primary diagnosis in 249 advanced-stage MCL patients treated within randomized trials. KI-67 showed high prognostic relevance for overall survival (relative risk 1.27 for 10% higher Ki-67, P < .001), also independently from clinical prognostic factors. The 3 groups with different Ki-67 index of less than 10%, 10% to less than 30%, and 30% or more showed significantly different overall survival in patients treated with CHOP (P = .001) as well as in patients treated with CHOP in combination with anti-CD20 therapy (R-CHOP, P = .013). Thus, the Ki-67 index remains an important prognostic marker in the era of anti-CD20 therapy. The European MCL study is registered at www. ClinicalTrials.gov as #NCT00016887.